Spyre Therapeutics, Inc. SYRE Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss
Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss at other companies
Other financials
Where this comes from
Reported directly by Spyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss.
The official record: Spyre Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Spyre Therapeutics, Inc.'s debt securities, available-for-sale, continuous unrealized loss position, 12 months or longer, accumulated loss.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Spyre Therapeutics, Inc.'s debt securities, available-for-sale, continuous unrealized loss position, 12 months or longer, accumulated loss?
- Spyre Therapeutics, Inc. (SYRE) reported debt securities, available-for-sale, continuous unrealized loss position, 12 months or longer, accumulated loss of $0 in Q1 2026.